Rain Therapeutics Inc

Company Profile

Rain Therapeutics Inc had its IPO on 2021-04-23 under the ticker symbol RAIN.

The company operates in the Healthcare sector and Biotechnology industry. Rain Therapeutics Inc has a staff strength of 63 employees.

Stock update

Shares of Rain Therapeutics Inc opened at $182.75 at the start of the last trading session i.e. 2023-09-13.

The stocks traded within a range of $167.3 - $182.75, and closed at $168.2.

This is a -7.25% slip from the previous day's closing price.

A total volume of 4,183,037 shares were traded at the close of the day’s session.

In the last one week, shares of Rain Therapeutics Inc have slipped by -1.81%.

Rain Therapeutics Inc's Key Ratios

Rain Therapeutics Inc has a market cap of $37.47 million, indicating a price to book ratio of 3.0259 and a price to sales ratio of 0.

In the last 12-months Rain Therapeutics Inc’s revenue was $0 with a gross profit of $0 and an EBITDA of $-84034000. The EBITDA ratio measures Rain Therapeutics Inc's overall financial performance and is widely used to measure its profitability.

In the trailing 12-month period, Rain Therapeutics Inc’s operating margin was 0% while its return on assets stood at -51.95% with a return of equity of -97.06%.

In Q2, Rain Therapeutics Inc’s quarterly earnings growth was a positive 0% while revenue growth was a positive 0%.

Rain Therapeutics Inc’s PE and PEG Ratio

Forward PE

0

Trailing PE

0

PEG

Its diluted EPS in the last 12-months stands at $-2.51 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of . A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.

The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Rain Therapeutics Inc’s profitability.

Rain Therapeutics Inc stock is trading at a EV to sales ratio of 0 and a EV to EBITDA ratio of -2.1825. Its price to sales ratio in the trailing 12-months stood at 0.

Rain Therapeutics Inc stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.

Balance sheet and cash flow metrics

Total Assets

$91.72 million

Total Liabilities

$18.33 million

Operating Cash Flow

$19.59 million

Capital Expenditure

$304000

Dividend Payout Ratio

0%

Rain Therapeutics Inc ended 2024 with $91.72 million in total assets and $0 in total liabilities. Its intangible assets were valued at $91.72 million while shareholder equity stood at $73.29 million.

Rain Therapeutics Inc ended 2024 with $0 in deferred long-term liabilities, $18.33 million in other current liabilities, 37000.00 in common stock, $-208236000.00 in retained earnings and $0 in goodwill. Its cash balance stood at $40.08 million and cash and short-term investments were $86.29 million. The company’s total short-term debt was $164,000 while long-term debt stood at $0.

Rain Therapeutics Inc’s total current assets stands at $90.99 million while long-term investments were $0 and short-term investments were $46.21 million. Its net receivables were $531000.00 compared to accounts payable of $5.80 million and inventory worth $3.99 million.

In 2024, Rain Therapeutics Inc's operating cash flow was $19.59 million while its capital expenditure stood at $304000.

Comparatively, Rain Therapeutics Inc paid $0 in dividends in 2024.

Other key metrics

Current Trading Price

$168.2

52-Week High

$14.48

52-Week Low

$0.87

Analyst Target Price

$5.81

Rain Therapeutics Inc stock is currently trading at $168.2 per share. It touched a 52-week high of $14.48 and a 52-week low of $14.48. Analysts tracking the stock have a 12-month average target price of $5.81.

Its 50-day moving average was $164.13 and 200-day moving average was $163.71 The short ratio stood at 3.55 indicating a short percent outstanding of 0%.

Around 1525.7% of the company’s stock are held by insiders while 9306.8% are held by institutions.